Connect with us

Health

Increase in deaths associated with anxiety drug pregabalin in the Department Of Health Sciences

Published

on

Department Of Health Sciences: Anxiety drug pregabalin linked to rising number of deaths

A significant increase in deaths related to the commonly prescribed anxiety drug, pregabalin, has raised concerns among health experts. In 2018, there were 187 deaths linked to pregabalin in England and Wales, but by 2022, this number more than doubled to 441 deaths. Recent press reports have drawn parallels with a “US-style opioid epidemic,” although such comparisons may be disproportionate due to the higher toll opioids have taken in the US.

Pregabalin, also known by the brand names Lyrica and Alzain, is used to treat epilepsy, nerve pain, and anxiety. It has rewarding properties that can induce feelings of euphoria and relaxation, making it appealing to some individuals without prescriptions. While pregabalin itself is not inherently dangerous, its interactions with other drugs, particularly opioids, can lead to fatal complications like respiratory suppression.

An analysis of pregabalin-related deaths in England from 2004 to 2020 revealed that over 90% of cases involved the presence of other opioids, even when not prescribed. The rise in pregabalin deaths coincides with an increase in prescriptions for the drug, emphasizing the need for increased awareness among patients and prescribers about the risks of dependency and drug interactions.

Certain demographics, such as individuals with a history of substance use disorder and those in socially deprived areas, may be at a higher risk of harm from pregabalin misuse. Understanding the factors contributing to these deaths is crucial for developing strategies to mitigate harm effectively. While stopping pregabalin prescriptions entirely may not be practical, education about the risks and interactions associated with the drug is essential to prevent further fatalities.

Click to comment

You must be logged in to post a comment Login

Leave a Reply

Trending